📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease. (2016)

First Author: Scott RA

Attributed to: Establishment of the Cambridge Single Cell Analysis Clinical Core Facility [SCACCF] funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1126/scitranslmed.aad3744

PubMed Identifier: 27252175

Publication URI: http://europepmc.org/abstract/MED/27252175

Type: Journal Article/Review

Volume: 8

Parent Publication: Science translational medicine

Issue: 341

ISSN: 1946-6234